

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- In the Headlines: What’s in Trump’s draft budget?
- NCI summarizes changes to the CCSG NOFO
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - AACR announces 2025 Scientific Achievement Award recipients